FIELD: medicine.SUBSTANCE: group of inventions relates to treatment of neurological diseases of central nervous system. Method of treatment of neurological disorder of central nervous system in patient includes introduction of therapeutically active quantities of composition including: a) at least one complex, which includes therapeutic polypeptide and block copolymer, where said block copolymer includes at least one water-soluble non-ionic segment and at least one poly-ionic segment, where said poly-ionic segment includes at least one charge, opposite to charge of therapeutic polypeptide, where said complex has morphology core-shell, where core contains water-soluble non-ionic segment of block copolymer, and where shell contains water-soluble non-ionic segment of block copolymer and b) at least one pharmaceutically acceptable carrier, where said at least one complex penetrates blood-brain barrier. Method of treating neurological disorder of central nervous system in patients includes introduction of therapeutically active quantities of composition including: a) isolated cells, containing at least one complex, which includes therapeutic polypeptide and block copolymer, where said block copolymer includes at least one water-soluble non-ionic segment and at least one poly-ionic segment, where said poly-ionic segment includes at least one charge, opposite to charge of therapeutic polypeptide, where said complex has morphology core-shell, where core contains therapeutic polypeptide and poly-ionic segment of block copolymer and where shell contains water-soluble non-ionic segment of block copolymer, and b) at least one pharmaceutically acceptable carrier, where said cells penetrate blood-brain barrier. Isolated cell, which contains at least one complex, containing at least one protein and block copolymer, where said copolymer includes at least one water-soluble non-ionic segment and at least one poly-ionic segment, where said poly-ionic segment contains at least one charge, opposite to charge of said protein, where said complex has morphology core-shell, where core contains therapeutic polypeptide and poly-ionic segment of bloc copolymer and where shell contains water-soluble non-ionic segment of block copolymer. Composition, containing said isolated cells and at least one pharmaceutically acceptable carrier. Method of protein delivery through blood-brain barrier into central nervous system, including introduction of said composition to subject. Method of protein delivery through blood-brain barrier into central nervous system, including introduction to patient of composition, containing: a) at least one complex, including therapeutic polypeptide and block copolymer, where said block copolymer includes at least one water-soluble non-ionic segment and at least one poly-ionic segment, where said poly-ionic segment includes at least one charge, opposite to charge of therapeutic polypeptide, where said complex has morphology core-shell, where core contains therapeutic polypeptide and poly-ionic segment of block copolymer and where shell contains water-soluble non-ionic segment of block copolymer, and b) at least one pharmaceutically acceptable carrier.EFFECT: group of inventions ensures increased efficiency of treatment of neurological diseases.39 cl, 23 dwg, 14 tbl, 12 ex